ClinicalTrials.gg
CompletedNCT01073865Updated Dec 12, 2018Results posted

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

A Phase 3 interventional study of ZD9393 (Zoladex) 10.8 mg and ZD9393 (Zoladex) 3.6 mg in Breast Cancer, sponsored by AstraZeneca. Completed at 55 sites in 6 countries. Open to female participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-12-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
20 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Enrollment
11th of 41
222 · median 147
Started
2010
with 1 other
Phase 3
15 of 43
none open now
Registered
18th of 43
by date
Lead sponsor
5 of 43
AstraZeneca

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2010, is one of 15 in phase 3, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced breast cancer who were randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • ZOLADEX
  • Pre-menopausal
  • Oestrogen Receptor
  • Advanced Breast Cancer
  • Progression Free Survival
04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female ≥20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 ≥10 pg/mL and FSH ≤ 30 mIU/mL within 4 weeks of randomisation.
  • Hormone sensitivity (ER positive) of primary or secondary tumour tissue.
  • Histological/cytological confirmation of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received tamoxifen or other hormonal therapies as therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer
  • Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation
  • Patients who have during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    1

    Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days). One oral tamoxifen 20 mg tablet also will be taken daily

    Drug: ZD9393 (Zoladex) 10.8 mg

  • Active comparator
    2

    Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.

    Drug: ZD9393 (Zoladex) 3.6 mg

Interventions

  • 10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).

    Also known as: Zoladex

  • 3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).

    Also known as: Zoladex

06

What researchers measure

Primary outcomes

  1. Number of Patients With Progression-free Survival (PFS) at 24 Weeks

    A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.

    Time frame: 24 weeks after the first dosing

Secondary outcomes

  1. Number of Responders at 24 Weeks

    Responders are defined as those patients with a best objective tumour response of CR or PR during the first 24 weeks of therapy. Tumour response is assessed according to the RECIST version 1.1. ORR is defined as the proportion of patients who are responders.

    Time frame: 24 weeks after the first dosing

  2. Oestradiol (E2) Serum Concentrations at 24 Weeks

    E2 serum concentrations (pg/mL) at 24 weeks

    Time frame: 24 weeks after the first dosing

07

Results

Posted Jan 10, 2014

Participant flow

Totally 286 patients were screened to the study from 58 centres in the following 6 countries: India, Japan, Korea, Philippines, Thailand, Taiwan. The first patient entered the study on 26 February 2010 and the last visit of last patient was on 19 September 2012.

Participant flow — Overall Study
MilestoneZoladex 10.8 mgZoladex 3.6 mg
Started109113
Received randomised treatment108113
Completed8174
Not completed2839
Withdrew: Reasons other than below1931
Withdrew: Lost to follow-up11
Withdrew: Death32
Withdrew: Withdrawal by subject55

Outcome measures

PrimaryNumber of Patients With Progression-free Survival (PFS) at 24 Weeks

A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.

Time frame:
24 weeks after the first dosing
Reported as:
Count of participants · Participants
Number of Patients With Progression-free Survival (PFS) at 24 Weeks
ParticipantsZoladex 10.8 mgZoladex 3.6 mg
Number of Patients With Progression-free Survival (PFS) at 24 Weeks6768
Statistical analysis
  • Zoladex 10.8 mg vs Zoladex 3.6 mg · Risk difference (rd): 1.29 · 95% CI -11.40 to 13.90%PFS at 24 weeks for Zoladex 10.8mg - %PFS at 24 weeks for Zoladex 3.6mg
SecondaryNumber of Responders at 24 Weeks

Responders are defined as those patients with a best objective tumour response of CR or PR during the first 24 weeks of therapy. Tumour response is assessed according to the RECIST version 1.1. ORR is defined as the proportion of patients who are responders.

Time frame:
24 weeks after the first dosing
Reported as:
Count of participants · Participants
Number of Responders at 24 Weeks
ParticipantsZoladex 10.8 mgZoladex 3.6 mg
Number of Responders at 24 Weeks2125
Statistical analysis
  • Zoladex 10.8 mg vs Zoladex 3.6 mg · Risk difference (rd): -3.02 · 95% CI -15.47 to 9.67ORR at 24 weeks for Zoladex 10.8mg - ORR at 24 weeks for Zoladex 3.6mg
SecondaryOestradiol (E2) Serum Concentrations at 24 Weeks

E2 serum concentrations (pg/mL) at 24 weeks

Time frame:
24 weeks after the first dosing
Reported as:
Mean · pg/mL
Oestradiol (E2) Serum Concentrations at 24 Weeks
pg/mLZoladex 10.8 mgZoladex 3.6 mg
Oestradiol (E2) Serum Concentrations at 24 Weeks20.302 ± 12.25124.798 ± 28.149

Adverse events

Collected over Non serious AEs and SAEs were be collected from the time of patient informed until 4 weeks after the final administration of ZOLADEX 3.6 mg or 12 weeks after the final administration of ZOLADEX 10.8 mg. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoladex 10.8 mg4/108 (3.7%)4/108 (3.7%)47/108 (43.5%)
Zoladex 3.6 mg3/113 (2.7%)8/113 (7.1%)52/113 (46%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventZoladex 10.8 mgZoladex 3.6 mg
DYSPNOEARespiratory, thoracic and mediastinal disorders0/1083/113
ANAEMIABlood and lymphatic system disorders1/1081/113
TETANUSInfections and infestations1/1080/113
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders1/1080/113
CHEST PAINGeneral disorders1/1080/113
ENTEROCOLITISGastrointestinal disorders0/1081/113
PERIODONTAL DISEASEGastrointestinal disorders0/1081/113
VOMITINGGastrointestinal disorders0/1081/113
PNEUMONIAInfections and infestations0/1081/113
MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders0/1081/113
Most frequent other events
Showing 10 of 14
Most frequent other events
EventZoladex 10.8 mgZoladex 3.6 mg
HOT FLUSHVascular disorders15/10822/113
NASOPHARYNGITISInfections and infestations13/1089/113
BACK PAINMusculoskeletal and connective tissue disorders5/1089/113
NAUSEAGastrointestinal disorders2/1089/113
HEADACHENervous system disorders7/1087/113
PYREXIAGeneral disorders2/1087/113
INSOMNIAPsychiatric disorders3/1086/113
CONSTIPATIONGastrointestinal disorders4/1085/113
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders3/1085/113
VOMITINGGastrointestinal disorders4/1083/113

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zoladex 10.8 mgZoladex 3.6 mgTotal
Mean40.9 ± 6.940.9 ± 6.040.9 ± 6.4
Sex: Female, Male
Sex: Female, Male(Participants)Zoladex 10.8 mgZoladex 3.6 mgTotal
Female109113222
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zoladex 10.8 mgZoladex 3.6 mgTotal
Hispanic or Latino000
Not Hispanic or Latino109113222
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoladex 10.8 mgZoladex 3.6 mgTotal
Asian109113222
Other000
Region of Enrollment
Region of Enrollment(Participants)Zoladex 10.8 mgZoladex 3.6 mgTotal
Asia — India292756
Asia — Japan293059
Asia — Philippines212344
Asia — Thailand10919
Asia — Taiwan7916
Asia — Republic of Korea131528
08

Study locations

55 sites
  • Research Site
    Ahmedabad, 380009, India
  • Research Site
    Bangalore, 560029, India
  • Research Site
    Bangalore, 560090, India
  • Research Site
    Chennai, 600010, India
  • Research Site
    Hubli, 580025, India
  • Research Site
    Hyderabad, 500024, India
  • Research Site
    Jaipur, 302017, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Nagpur, 440012, India
  • Research Site
    New Delhi, 110060, India
  • Research Site
    New Delhi, 110085, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Pune, 411004, India
  • Research Site
    Pune, 411005, India
  • Research Site
    Thiruvananthapuram, 695011, India
  • Research Site
    Amagasaki-shi, 660-8511, Japan
  • Research Site
    Chiba, 260-8717, Japan
  • Research Site
    Chuo-ku, 104-8560, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Hamamatsu, 430-0906, Japan
  • Research Site
    Hiroshima-shi, 730-8518, Japan
  • Research Site
    Kagoshima-shi, 892-0833, Japan
  • Research Site
    Kamogawa-shi, 296-0041, Japan
  • Research Site
    Kitaadachi, 362-0806, Japan
  • Research Site
    Kumamoto-shi, 862-8505, Japan
  • Research Site
    Kyoto-shi, 602-8566, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Nagoya-shi, 465-0024, Japan
  • Research Site
    Niigata-shi, 951-8566, Japan
  • Research Site
    Osaka-shi, 553-0003, Japan
  • Research Site
    Osaka, 540-0006, Japan
  • Research Site
    Sakai-shi, 593-8304, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 139-706, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Cebu City, 6000, Philippines
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Lipa City, 4217, Philippines
  • Research Site
    Pasay City, Philippines
  • Research Site
    Quezon City, 1104, Philippines
  • Research Site
    Quezon City, Philippines
  • Research Site
    Kaohsiung, 807, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Maharat Nakorn Ratchasima, 30000, Thailand
  • Research Site
    Songkla, 90110, Thailand
  • Research Site
    Ubonratchathani, 34000, Thailand
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Sep 2012, 30 months.

Results were first posted in Jan 2014, 1 year 3 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 30 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 23, 2010
StartActual
Feb 26, 2010
Primary completionActual
Sep 19, 2012
CompletionActual
Nov 20, 2017
Results first posted
Jan 10, 2014
Last update
Dec 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01073865
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 23, 2010
Start date
Feb 26, 2010
Primary completion
Sep 19, 2012
Completion
Nov 20, 2017
Results posted
Jan 10, 2014
Last update
Dec 12, 2018

Study contacts

Justin Lindemann, PO
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion